Medical therapy of children with fibrous dysplasia

Journal of Bone and Mineral Research

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Glorieux, Francis H ^a,b   Rauch, Frank ^a  

^a MCGILL UNIVERSITY   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ACUTE PHASE RESPONSE; ARTICLE; BONE METABOLISM; BONE MINERALIZATION; BONE PAIN; BONE STRUCTURE; BONE TURNOVER; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE SEVERITY; FIBROUS DYSPLASIA; HUMAN; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOMALACIA; RICKETS; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME; CHILD; REVIEW;

CHILD; DIPHOSPHONATES; FIBROUS DYSPLASIA OF BONE; HUMANS;

EID: 34247869961     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.06S221     Document Type: Article

References (37)

1. Lichtenstein L, Jaffe HL 1942 Fibrous dysplasia of bone. Arch Pathol 33:777-816.
2. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG 2001 Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 16:806-813.
3. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespak S, Gupta A, Hannon T, Econs MJ, Bianco P, Robey PG 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692.
4. Yamamoto T 2006 Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome. J Bone Miner Metab 24:7-10.
5. Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, Goto H, Ohashi H, Koyano HM, Mochizuki R, Miki T, Inaba M, Nishizawa Y 2006 Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 78:2295-2301.
6. Cole DE, Fraser FC, Glorieux FH, Jequier S, Marie PJ, Reade TM, Scriver CR 1983 Panostotic fibrous dysplasia: A congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemia. Am J Med Genet 14:725-735.
7. Albright F, Butler AM, Hampton AO, Smith P 1937 Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunctions, with precocious puberty in females. N Engl J Med 216:727-746.
8. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695.
9. Happle R 1986 The McCune-Albright syndrome: A lethal gene surviving by mosaicism. Clin Genet 29:321-324.
10. Schwindinger WF, Francomano CA, Levine MA 1992 Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 89:5152-5156.
11. Malchoff CD, Reardon G, MacGillivray DC, Yamase H, Rogol AD, Malchoff DM 1994 An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab 78:803-806.
12. Shenker A, Weinstein LS, Sweet DE, Spiegel AM 1994 An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 79:750-755.
13. Candeliere GA, Roughley PJ, Glorieux FH 1997 Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in G alpha s from patients with fibrous dysplasia of bone. Bone 21:201-206.
14. Candeliere GA, Glorieux FH, Prud'homme J, St-Arnaud R 1995 Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332:1546-1551.
15. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S 1996 Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 98:30-35.
16. Marie PJ, de Pollak C, Chanson P, Lomri A 1997 Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 150:1059-1069.
17. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P 1997 Fibrous dysplasia of bone in the McCune-Albright syndrome: Abnormalities in bone formation. Am J Pathol 151:1587-1600.
18. Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Robey PG, Bianco P 1999 The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: Site-specific patterns and recurrent histological hallmarks. J Pathol 187:249-258.
19. Harris WH, Dudley HR, Barry RJ 1962 The natural history of fibrous dysplasia. J Bone Joint Surg Am 44:207-233.
20. Terpstra L, Rauch F, Plotkin H, Travers R, Glorieux FH 2002 Bone mineralization in polyostotic fibrous dysplasia: Histomorphometric analysis. J Bone Miner Res 17:1949-1953.
21. Dent CE, Gertner JM 1976 Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 45:411-420.
22. Tanaka T, Suwa S 1977 A case of McCune-Albright syndrome with hyperthyroidism and vitamin D-resistant rickets. Helv Paediatr Acta 32:263-273.
23. Zung A, Chalew SA, Schwindinger WF, Levine MA, Phillip M, Jara A, Counts DR, Kowarski AA 1995 Urinary cyclic adenosine 3′,5′-monophosphate response in McCune-Albright syndrome: Clinical evidence for altered renal adenylate cyclase activity. J Clin Endocrinol Metab 80:3576-3581.
24. Ruggieri P, Sim FH, Bond JR, Unni KK 1994 Malignancies in fibrous dysplasia. Cancer 73:1411-1424.
25. Stephenson RB, London MD, Hankin FM, Kaufer H 1987 Fibrous dysplasia. An analysis of options for treatment. J Bone Joint Surg Am 69:400-409.
26. Ozaki T, Sugihara M, Nakatsuka Y, Kawai A, Inoue H 1996 Polyostotic fibrous dysplasia. A long-term follow up of 8 patients. Int Orthop 20:227-232.
27. Bell NH, Avery S, Johnston CC 1970 Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia. J Clin Endocrinol Metab 31:283-290.
28. Yamamoto K, Maeyama I, Kishimoto H, Morio Y, Harada Y, Ishitobi K, Ishikawa J 1983 Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive urinary hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome). Endocrinol Jpn 30:651-656.
29. Hjelmstedt A, Ljunghall S 1979 A case of Albright's syndrome treated with calcitonin. Acta Orthop Scand 50:251-253.
30. Chapurlat RD, Delmas PD, Liens D, Meunier PJ 1997 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746-1752.
31. Pfeilschifter J, Ziegler R 1998 Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome. Med Klin 93:352-359.
32. Lane JM, Khan SN, O'Connor WJ, Nydick M, Kommen JP, Schneider R, Tomin E, Brand J, Curtin J 2001 Bisphosphonate therapy in fibrous dysplasia. Clin Orthop 382:6-12.
33. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C 2000 Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 89:188-193.
34. Zacharin M, O'Sullivan M 2000 Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 137:403-409.
35. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH 2003 Effect of Pamidronate Treatment in Children with Polyostotic Fibrous Dysplasia of Bone. J Clin Endocrinol Metab 88:4569-4575.
36. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
37. Weinstein RS 1997 Long-term aminobisphosphonate treatment of fibrous dysplasia: Spectacular increase in bone density. J Bone Miner Res 12:1314-1315.